Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period
Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period Moneycontrol Latest News Read More